Biotrader

@rogerclemens @Captain2Corner Yankees infield defense not good enough - what do you think?

@Captain2Corner Pitching/Defense wins championships

Baseball fans… How are you feeling about your team so far this year? I wanna hear some thoughts…

@ChrisKirschner Boone and Yankees analytics think they are smarter than everyone else

I spoke with Aaron Boone about Ben Rice not starting 4 of 5 matchups vs. LHP and asked straight up if he considers him a platoon player. “Hell no,” Boone said. So what’s going on? More from Boone and Rice ⬇️ nytimes.com/athletic/71969…

@AppleTV This show sucks, nobody has a RING camera? Really? Stupid.

Watch Your Friends & Neighbors Season 2, starring Jon Hamm on Apple TV.

@Jomboy_ Where are the coaches? For real

Caballero telling McMahon 'go touch first dude' before celebrating with him

@pamsson @sondraa 1000000%!!!!

Why is Grichuk hitting there? You’re better off with Goldy. Why is Grichuk swinging first pitch? At this point, everyone is better off with Jasson as the fourth OF. Just finish his development in the majors. He could’ve had all of these Grichuk at bats.

@JackCurryYES why not give The Martian some big league at Bats instead of Grichuk? Grichuk at bats have been anemic. Invest in Jasson instead. Dont get it

@SquawkCNBC @fundstrat Broken clock is right 2x per day

@fundstrat's Tom Lee expects March to be an up month for the stock markets: cnb.cx/4qYwOZD

@TheTennisLetter Letting toss drop too much, its always someone else’s fault though

Coco Gauff after hitting a double fault against Elina Svitolina in Dubai "I've been doing everything you've wanted for the last 6 months..." This is presumably to her biomechanics expert, Gavin MacMillan, who she hired before the US Open last season to help with her serve.

@elonmusk I love my FSD also, but in the past month it almost ran through 2 school buses stopped with lights on and it constantly tries to turn right on “no turn on red” intersections. Will it learn?

You really will. It’s awesome.

@MeadowCapital A lot has happened since then. Including most favored nation, other pharma getting into glp, and novo oral launched.

@biotraderusa Literally your previous post is : "I think $VKTX have a commercially viable drug but I don't want to wait 2-3 years."

$vktx too late to the GLP1 game, pricing pressure and high cogs results in low margins, differentiation is minimal when so late to the game…need big pharma to compete commercially and they all passed. Game over in weight loss. MASH has potential.

@vtcarguy81 Need volume

@biotraderusa At scale margins will not be a problem

@iAnonPatriot Omg so cringe

Never forget when Kamala Harris acted like she got a call from a “voter”, but it ended up just being the camera app… LMAO

@itsJohnRocker LoL hypocrite

I'm on way to Colombia for stem cell treatment to hopefully fix my back that's becoming agonizingly painful. Updates to come.

@AndrewBrandt He looks white chocolate from the Sacramento Kings

As a parent and as a son, this brought out all the feels..

@DougKass @POTUS That post is fake Doug

@Pharmdca Pricing and reimbursement dynamics have cratered and will only get worse when LLY and NOVO drugs negotiate with CMS, then MFN risk. VKTX missed the window.

$VKTX too cheap here. Currently, market doesn't take into consideration that their obesity franchise is very competitive vs $LLY drugs and could be the next winner when company reports ph3 results. Though, stock has underperformed for a while, but with upcoming maintenance data this year, think stock will have a turnaround story onwards. Compelling opportunity long term.

@TalkinYanks The Dodgers 2026 payroll you mentioned, that assumes only $3 million for Shohei and Tucker, right?

Bellinger's Contract is Crazy + Yanks Still Need a Righty Bat 0:00 Bellinger's Contract and What It Might Mean 23:30 Righties off the Bench 30:20 What We're Excited For in Spring Training 34:55 Relievers

@TimCarmichael3 Wow, PFE just burning shareholder value with one bad deal after another…

Pfizer dips on new data for obesity drug acquired in $10B deal | BioPharma Dive. $PFE biopharmadive.com/news/pfizer-ob…

@adamfeuerstein Yes that’s a joke

@biotraderusa Reporting n=4 is highly misleading, but that's what $IBRX chose to do.

$IBRX NK cell therapy showing 50% durable CR rate in indolent NHL (and just WM) is suboptimal, lower than competing allogeneic and autologous CAR-Ts.